Abstract:Background: NOTCH3 signaling is required for the proliferation of vascular smooth muscle cells. NOTCH3 signaling has been implicated in the development of pulmonary arterial hypertension (PAH) as reflected by increased levels of cleaved NOTCH3 and its downstream effector, HES-5 in small pulmonary artery smooth muscle cells (PASMCS) of PAH patients. Gamma-secretase inhibitor drugs that block NOTCH cleavage are effective in treating pulmonary hypertension (PH) in rodents, but they are associated with toxic side effects. Hypothesis: We hypothesize that a monoclonal antibody that specifically blocks NOTCH3 cleavage will effectively reverse PH in rodent models of disease, with an acceptable safety profile. Methods/Results: A monoclonal antibody specific to rodent and human NOTCH3 (Anti-NOTCH3 Ab) was made and shown to block Jagged-1/Delta-like 4-mediated NOTCH3 cleavage in PASMCs in vitro . We tested Anti-NOTCH3 Ab for its ability to reverse PH in mouse hypoxia and rat Sugen models. After 4 weeks of hypoxia, mice treated with Anti-NOTCH3 Ab for 6 weeks demonstrated normalization of right ventricular systolic pressure (mean 17 mmHg), compared to RVSP in control mice (mean 35mmHg). Treated mice demonstrated reversal of small vessel remodeling and had angiograms consistent with normal vasculature. In the Sugen model, rats treated with Anti-NOTCH3 Ab for 10 weeks showed reversal of established disease. This included normalization of RVSPs (mean 18 mmHg - treated group vs. 70 mmHg - control group), normalization of TAPSE values (mean 3.7 mm - treated group vs. 2.4 mm - control group) and normalization of PAAT values (mean 42 msec - treated group vs. 17 msec - control group). The lungs of Anti-NOTCH3 Ab-treated rats had reversal of small vessel remodeling with loss of medial hypertrophy. Western blot analysis showed significantly decreased cleavage of NOTCH3 in the treated group vs. control group. Anti-NOTCH3 Ab-treated rodents did not manifest clinical side effects and had normal organ histology of brain, liver, kidney, intestine, skin, ovary, and heart. Conclusion: Inhibition of cleavage of NOTCH3 by a monoclonal Anti-NOTCH3 Ab effectively treats PH in mouse hypoxia and rat Sugen models. Anti-NOTCH3 Ab treatment was associated with an acceptable safety profile.

Reduced Notch1 Cleavage Promotes the Development of Pulmonary Hypertension

Effect of the Notch4/Dll4 Signaling Pathway in Early Gestational Intrauterine Infection on Lung Development

Notch3 signaling activation in smooth muscle cells promotes extrauterine growth restriction-induced pulmonary hypertension.

Notch Signaling Change in Pulmonary Vascular Remodeling in Rats with Pulmonary Hypertension and Its Implication for Therapeutic Intervention.

Abstract 12164: Inhibition of NOTCH3 Cleavage Effectively Reverses Pulmonary Hypertension in Rat and Mouse Models of Disease

Inhibition of DLL4/Notch Signaling Pathway Promotes M2 Polarization and Cell Proliferation in Pulmonary Arterial Hypertension

Notch Signaling: Linking Embryonic Lung Development and Asthmatic Airway Remodeling

Notch4 mediates vascular remodeling via ERK/JNK/P38 MAPK signaling pathways in hypoxic pulmonary hypertension

MED1 Regulates BMP/TGF- in Endothelium: Implication for Pulmonary Hypertension

JAGGED-NOTCH3 signaling in vascular remodeling in pulmonary arterial hypertension

Abstract 108: Mediator 1 Regulation of the BMP / TGF-β Signaling in Endothelium: Implications for Pulmonary Hypertension

MED1 Regulates BMP/TGF-β in Endothelium: Implication for Pulmonary Hypertension

Disruption of DLL4/NOTCH1 Causes Dysregulated PPARγ/AKT Signaling in Pulmonary Arterial Hypertension

Deficiency in DDR1 Induces Pulmonary Hypertension and Impaired Alveolar Development

Notch3/Hes5 Induces Vascular Dysfunction in Hypoxia-Induced Pulmonary Hypertension Through ER Stress and Redox-Sensitive Pathways

Abstract 4119213: A Novel Animal Model for Pulmonary Hypertension: Lung Endothelial Specific Deletion of Egln1 in Mice

LINC00599 Promotes Pulmonary Hypertension via LLPS with G3BP1 and MYH9

Functional Roles of CD26/DPP4 in Bleomycin-Induced Pulmonary Hypertension Associated with Interstitial Lung Disease

A Novel Animal Model for Pulmonary Hypertension: Lung Endothelial-Specific Deletion of Egln1 in Mice.

Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2α

Notch activation of Ca 2+ -sensing receptor mediates hypoxia-induced pulmonary hypertension